FI55503C - Foerfarande foer framstaellning av terapeutiskt anvaendbara pyrimidinonderivat - Google Patents

Foerfarande foer framstaellning av terapeutiskt anvaendbara pyrimidinonderivat

Info

Publication number
FI55503C
FI55503C FI2825/72A FI282572A FI55503C FI 55503 C FI55503 C FI 55503C FI 2825/72 A FI2825/72 A FI 2825/72A FI 282572 A FI282572 A FI 282572A FI 55503 C FI55503 C FI 55503C
Authority
FI
Finland
Prior art keywords
pyrimidinonderivat
framework
preparation
therapeutic animal
animal thermal
Prior art date
Application number
FI2825/72A
Other languages
English (en)
Finnish (fi)
Other versions
FI55503B (fi
Inventor
Christopher Andrew Lipinski
John Gerritt Stam
Gerald George De Angelis
Hans-Jurgen Ernst Hess
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Priority to FI781204A priority Critical patent/FI55504C/fi
Publication of FI55503B publication Critical patent/FI55503B/fi
Application granted granted Critical
Publication of FI55503C publication Critical patent/FI55503C/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56One oxygen atom and one sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60Three or more oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FI2825/72A 1971-10-29 1972-10-12 Foerfarande foer framstaellning av terapeutiskt anvaendbara pyrimidinonderivat FI55503C (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI781204A FI55504C (fi) 1971-10-29 1978-04-19 Foerfarande foer framstaellning av nya terapeutiskt anvaendbara hydroxi-pyrimidiner

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19400671A 1971-10-29 1971-10-29

Publications (2)

Publication Number Publication Date
FI55503B FI55503B (fi) 1979-04-30
FI55503C true FI55503C (fi) 1979-08-10

Family

ID=22715935

Family Applications (1)

Application Number Title Priority Date Filing Date
FI2825/72A FI55503C (fi) 1971-10-29 1972-10-12 Foerfarande foer framstaellning av terapeutiskt anvaendbara pyrimidinonderivat

Country Status (25)

Country Link
JP (2) JPS5337870B2 (ru)
AR (2) AR198798A1 (ru)
AT (2) AT321308B (ru)
AU (1) AU467600B2 (ru)
BE (1) BE790125A (ru)
CA (1) CA980778A (ru)
CH (2) CH555832A (ru)
DE (3) DE2248741C3 (ru)
DK (1) DK131465B (ru)
EG (1) EG11013A (ru)
ES (2) ES407730A1 (ru)
FI (1) FI55503C (ru)
FR (1) FR2157865B1 (ru)
GB (2) GB1377308A (ru)
IE (1) IE37043B1 (ru)
IL (2) IL40458A (ru)
LU (1) LU66304A1 (ru)
NL (1) NL166470C (ru)
NO (1) NO136574C (ru)
PH (2) PH10129A (ru)
PL (2) PL84634B1 (ru)
SE (2) SE393376B (ru)
SU (2) SU498908A3 (ru)
YU (2) YU35125B (ru)
ZA (1) ZA727362B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55151912U (ru) * 1979-04-17 1980-11-01
JPS5752409Y2 (ru) * 1979-11-05 1982-11-15
DE3222914A1 (de) * 1982-06-18 1983-12-22 Beiersdorf Ag, 2000 Hamburg Substituierte 5-phenylthio-6-amino-pyrimidinone, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen
JPH0655686B2 (ja) * 1988-08-30 1994-07-27 宇部興産株式会社 p−ブロモフェノキシアセトアルデヒドジアルキルアセタール類の製造方法
ATE533488T1 (de) 2005-08-22 2011-12-15 Melior Pharmaceuticals I Inc Verfahren und formulierungen zur modulierung von lyn-kinaseaktivität und behandlung assoziierter erkrankungen
US8552184B2 (en) 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
US20130158055A1 (en) 2010-05-28 2013-06-20 Andrew G. Reaume Prevention Of Pancreatic Beta Cell Degeneration
EP3609500B1 (en) 2017-04-10 2024-11-13 Melior Pharmaceuticals I, Inc. Treatment of adipocytes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913462A (en) * 1959-11-17 Eahl h
GB951432A (en) * 1959-03-17 1964-03-04 Wellcome Found Pyrimidine derivatives and the manufacture thereof

Also Published As

Publication number Publication date
DE2264374A1 (de) 1973-05-24
SE393376B (sv) 1977-05-09
PH10129A (en) 1976-09-02
NL166470C (nl) 1981-08-17
YU36295B (en) 1982-06-18
YU255172A (en) 1980-03-15
FR2157865B1 (ru) 1975-10-31
PH11594A (en) 1978-03-31
DE2264374C3 (de) 1981-07-23
GB1377308A (en) 1974-12-11
JPS4852780A (ru) 1973-07-24
AU467600B2 (en) 1975-12-04
IE37043B1 (en) 1977-04-27
NL166470B (nl) 1981-03-16
AU4722872A (en) 1974-04-04
DE2264657C2 (de) 1982-09-16
EG11013A (en) 1976-11-30
AR198798A1 (es) 1974-07-24
CH555832A (fr) 1974-11-15
CH549579A (fr) 1974-05-31
DK131465C (ru) 1975-12-08
YU99179A (en) 1981-08-31
DE2248741A1 (de) 1973-05-03
SU505362A3 (ru) 1976-02-28
JPS5422995B2 (ru) 1979-08-10
AT321308B (de) 1975-03-25
IL40458A0 (en) 1972-11-28
BE790125A (fr) 1973-04-16
SE7505279L (sv) 1975-05-06
SE397090B (sv) 1977-10-17
IL40458A (en) 1976-05-31
GB1377720A (en) 1974-12-18
DE2248741B2 (de) 1974-11-14
FI55503B (fi) 1979-04-30
ZA727362B (en) 1973-11-28
YU35125B (en) 1980-09-25
PL89852B1 (ru) 1976-12-31
DE2264657A1 (de) 1974-06-20
DK131465B (da) 1975-07-21
DE2248741C3 (de) 1975-06-26
JPS53116386A (en) 1978-10-11
FR2157865A1 (ru) 1973-06-08
ES436624A1 (es) 1977-02-01
CA980778A (en) 1975-12-30
JPS5337870B2 (ru) 1978-10-12
IE37043L (en) 1973-04-29
NL7213959A (ru) 1973-05-02
ES407730A1 (es) 1976-01-16
NO136574B (ru) 1977-06-20
IL48790A0 (en) 1976-03-31
NO136574C (no) 1977-09-28
IL48790A (en) 1976-05-31
AT320656B (de) 1975-02-25
SU498908A3 (ru) 1976-01-05
PL84634B1 (ru) 1976-04-30
AR196263A1 (es) 1973-12-10
DE2264374B2 (de) 1980-08-07
LU66304A1 (ru) 1973-05-03

Similar Documents

Publication Publication Date Title
SE392269B (sv) Forfarande for framstellning av vissa indanyloxitetrazoler
SE398877B (sv) Forfarande for framstellning av 14-hydroxi-morfinanderivat
SE400292B (sv) Forfarande for framstellning av benshydryl-3-karbamoyloximetyl-7-tienylacetamido-7-metoxidecefalosporanat
SE399701B (sv) Forfarande for framstellning av hydroxyalkyldiamin
FI55503C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara pyrimidinonderivat
SE394436B (sv) Forfarande for framstellning av 7-halogen-linkomyciner
FI54602C (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 6-amidinopenicillansyraderivat
SE417200B (sv) Forfarande for framstellning av 2-nitro-5-imidazolaldehydderivat
SE405478B (sv) Forfarande for framstellning av alfa-sulfoacylcefalosporiner
SE412756B (sv) Alternativa forfarande for framstellning av 2-(aminofenylimino)-3-aza-1-tia-cykloalkaner
SE385011B (sv) Forfarande for framstellning av alfa-linkosaminider
SE384686B (sv) Forfarande for framstellning av linkomycinderivat
SE408418B (sv) Forfarande for framstellning av 5-fluor-pyrimidiner
SE408177B (sv) Forfarande for framstellning av 4-hydroximetyl-1-ftalazonderivat
SE387936B (sv) Forfarande for framstellning av substituerade metoxiaminer
SE380520B (sv) Forfarande for framstellning av 1-cinnamylidenamino-3-bensylidenaminoguanidin
SE380795B (sv) Forfarande for framstellning av tiokarbamider
SE386897B (sv) Forfarande for framstellning av n-acyl-(piperazinoetyl)-pyrazoler
SE392902B (sv) Forfarande for framstellning av fenylimidazolidinoner
SE382046B (sv) Forfarande for framstellning av 1-aryloxi-2-propanol
SE397350B (sv) Forfarande for framstellning av tieno-diazepinderivat
SE405730B (sv) Forfarande for framstellning av kinazolinderivat
SE407061B (sv) Forfarande for framstellning av bensylpyrimidiner
SE387948B (sv) Forfarande for framstellning av tiofen
SE392724B (sv) Forfarande for framstellning av 7-aminocefalosporansyra